Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...

Pharmaceutical Equivalents

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs.

PharmacoEconomics - open·2026

Same author

Impact of Increased Single-Inhaler Triple Therapy Use in Appropriate Patients on Chronic Obstructive Pulmonary Disease Exacerbations, Mortality, and Medical Costs: PROMETHEUS Spain.

Respiration; international review of thoracic diseases·2025

Same author

Policies to promote affordability and access across the life cycle of costly new drugs.

BMJ (Clinical research ed.)·2025

Same author

Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements.

BMJ (Clinical research ed.)·2025

Same author

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons.

Rheumatology and therapy·2025

Same author

Patient Expectations in Allergic Rhinitis Treatment: A Mixed-Methods Study.

Patient preference and adherence·2025

Search research articles

Related Experiment Video

Updated: May 4, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Value-based differential pricing: efficient prices for drugs in a global context.

Patricia Danzon¹, Adrian Towse, Jorge Mestre-Ferrandiz

¹The Wharton School, University of Pennsylvania, Philadelphia, PA, USA.

Health Economics

|December 12, 2013

Summary

This study examines pharmaceutical pricing strategies to improve efficiency. Value-based pricing, considering willingness-to-pay and cost-effectiveness, can align prices with economic efficiency in countries with and without universal insurance.

Keywords:

ICER thresholds differential pricing value-based pricing

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

Related Experiment Videos

Last Updated: May 4, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

Area of Science:

Health Economics
Pharmaceutical Policy
Market Efficiency

Background:

Universal health insurance can reduce patient price sensitivity, potentially leading to inefficiently high pharmaceutical prices.
Pharmaceutical pricing strategies significantly impact healthcare system efficiency and affordability.
Countries differ in insurance coverage, affecting drug pricing and patient access.

Purpose of the Study:

To analyze pharmaceutical pricing strategies for achieving second-best static and dynamic efficiency.
To compare pricing mechanisms in countries with and without universal insurance.
To explore methods for improving pharmaceutical pricing efficiency and equity.

Main Methods:

Comparative analysis of pharmaceutical pricing models across different national healthcare systems.
Economic modeling to assess static and dynamic efficiency under various insurance and pricing scenarios.
Examination of value-based pricing, incremental cost-effectiveness ratios (ICERs), and price discrimination.

Main Results:

In universal insurance systems, value-based pricing aligned with ICER thresholds can achieve efficiency.
Cross-national price differentials are expected to correlate with per capita income, aligning with Ramsey optimal pricing.
Countries without insurance face challenges in affordability and require improved regulation and price discrimination.

Conclusions:

Pharmaceutical pricing can be optimized for efficiency using value-based approaches, particularly in systems with universal insurance.
Addressing price sensitivity and ensuring affordability requires tailored strategies based on national insurance structures.
Improving regulation and enabling price discrimination are key for enhancing efficiency in self-pay pharmaceutical markets.